SCHEMBL2266970

SCHEMBL2266970

CC(C)(C)NC(=O)CC1CCN(c2ncc(Cl)cc2NC(=O)c2cccc(Cl)c2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 3/20 0.64
CACNA1H O95180 2/20 0.47
CACNA1I Q9P0X4 2/20 0.45
KCNH2 Q12809 1/20 0.45
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41
LMNA P02545 2/20 0.40
MAPT P10636 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
GAA P10253 1/20 0.40
KCNMA1 Q12791 1/20 0.40
IRAK4 Q9NWZ3 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
KCNQ3 O43525 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2266380 0.91 CXCR3 (0.60) CXCR3CACNA1HCACNA1IKCNH2MEN1
SCHEMBL2264590 0.90 CXCR3 (0.53) CXCR3CACNA1HCACNA1IKCNH2MEN1
SCHEMBL2221310 0.90 CXCR3 (0.55) CXCR3CACNA1HCACNA1IKCNH2
SCHEMBL2223364 0.90 CXCR3 (0.53) CXCR3CACNA1HCACNA1IKCNH2MEN1
SCHEMBL12516581 0.87 CXCR3 (0.67) CXCR3CACNA1IKCNH2MEN1KMT2A
SCHEMBL2221970 0.87 CXCR3 (0.67) CXCR3MEN1KMT2ALMNAMAPT
SCHEMBL12515722 0.85 CXCR3 (0.72) CXCR3CACNA1IKCNH2MEN1KMT2A
SCHEMBL2267498 0.85 CXCR3 (0.72) CXCR3CACNA1IKCNH2MEN1KMT2A
SCHEMBL2272677 0.85 CXCR3 (0.68) CXCR3MEN1KMT2AKCNQ3KCNQ2
SCHEMBL2267018 0.84 CXCR3 (0.68) CXCR3CACNA1IKCNH2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US claimed
WO-2011084985-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-14 WO claimed
US-8952004-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-8952004-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
WO-2011084985-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-14 WO disclosed
WO-2011084985-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 CXCR3 1/4885CACNA1H 3046/4885CACNA1I 2871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.